# Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

> **NCT01519427** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 2 (actual)

## Conditions studied

- Recurrent Melanoma
- Stage IIIA Melanoma
- Stage IIIB Melanoma
- Stage IIIC Melanoma
- Stage IV Melanoma

## Interventions

- **DRUG:** Akt inhibitor MK2206
- **DRUG:** selumetinib
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01519427
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-01
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Study terminated due to slow accrual
- **Last updated:** 2014-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01519427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01519427, "Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01519427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*